Bio-Rad grants Nanogen licence to HH (hereditary haemochromatosis) gene mutations:
This article was originally published in Clinica
Executive Summary
Hercules, California-based Bio-Rad has granted Nanogen a licence to the C282Y and H63D gene mutations of the hereditary haemochromatosis (HH) disorder, which results in excessive iron build-up in tissues and major organs of the body. The licence is for use on Nanogen's proprietary NanoChip system for the detection of genetic mutations. Earlier this month, Nanogen, of San Diego, California, was granted a US patent covering methods for detecting certain mutations linked to the condition (see Clinica No 1011, p 2).